Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/15440

Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-beta


Vista previa

Ver/Abrir:
 Serum_Munoz_et_al_Sci_Reports_2022.pdf

1,78 MB
Adobe PDF
Título : Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-beta
Autor : Muñoz Morón, Úrsula
Escudero Lirola, Esther
Urcelay, Elena
Arroyo, Rafael
García-Martínez, Maria A.
Quintana, Francisco J.
Álvarez Lafuente, Roberto
Sádaba Argaiz, María Cruz
Materias: AutoimmunityBiochemistryBiological techniquesBiotechnologyDemyelinating diseasesImmunologyImmunosuppressionMultiple sclerosisNeurosciencePredictive markers
Editorial : Nature Research
Citación : Muñoz, Ú., Sebal, C., Escudero, E. et al. Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β. Sci Rep 12, 13357 (2022). https://doi.org/10.1038/s41598-022-16218-y
Resumen : We developed an ELISA assay demonstrating the high prevalence of serum IgM to phosphatidylcholine (IgM-PC) in the first stages of multiple sclerosis (MS). We aimed to analyze the role of serum IgM-PC as a biomarker of response to treatment. Paired serum samples from 95 MS patients were obtained before (b.t) and after (a.t) treatment with disease modifying therapies. Patients were classified as non-responders or responders to treatment, according to classical criteria. Serum IgM-PC concentration was analyzed using our house ELISA assay. The level of serum IgM-PC b.t was higher in patients treated later with natalizumab than in those treated with Copaxone (p = 0.011) or interferon-β (p = 0.009). Responders to natalizumab showed higher concentration of serum IgM-PC b.t than those who did not respond to it (p = 0.019). The 73.3% of patients with the highest level of serum IgM-PC b.t responded to natalizumab. IgM-PC level decreased a.t in both cases, non-responders and responders to natalizumab. IgM-PC levels a.t did not decrease in non-responders to interferon-β, but in responders to it the IgM-PC level decreased (p = 0.007). Serum IgM-PC could be a biomarker of response to natalizumab or interferon-β treatment. Further studies would be necessary to validate these results.
URI : http://hdl.handle.net/10637/15440
Derechos: http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
OpenAccess
ISSN : 2045-2322
Fecha de publicación : 3-ago-2022
Centro : Universidad San Pablo-CEU
Aparece en las colecciones: Medicina





Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.